Q: With the news today about Ibrance, what do you see for PFE going forward? How big is the bad news? Time to exit?
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
Q: I have not seen any questions in the last 1.5 years. May i have your current outlook for this company please. thanks
Q: The bottom fell out of this one. Your opinion, please, buy more, sell and hold on?
Q: what are your thoughts on this company? motley fool has been recommending and leadership looks good. how is the valuation and future growth?
Q: Hi,
Is it a good time to invest in this stock and does it have even cashflow to see through the development of the product.
Thank you
Is it a good time to invest in this stock and does it have even cashflow to see through the development of the product.
Thank you
Q: In view of the GBT acquisition, expected increase in revenues, what would be a fair price based on the industry average PE ratios, at the end of 2020 ? Do you think GUD will remain in the dog house for investors much longer ? I would have thought the GBT acquisition would have have changed investor sentiment, but clearly has not. What needs to happen to move the stock ?
Thanks
Thanks
Q: Hi,
What is your valued opinion of Kneat these days?
The last question on Nov 2019 indicated the sales valuation at 12x was concerning. Has that number come down enough for you to be more favourable as a spec buy.
They recently had another good quarter (Q1) with good % increases (albeit likely from a small base). They seem to be signing a number of contract wins last few quarters and I like that it is a SaaS based revenue model company.
Who might their other competitors be in this field? And any idea what their market penetration might be, for the competitors or for Kneat?
It would be for a spec buy and to initiate a 1/3 position.
Cheers,
Steve
What is your valued opinion of Kneat these days?
The last question on Nov 2019 indicated the sales valuation at 12x was concerning. Has that number come down enough for you to be more favourable as a spec buy.
They recently had another good quarter (Q1) with good % increases (albeit likely from a small base). They seem to be signing a number of contract wins last few quarters and I like that it is a SaaS based revenue model company.
Who might their other competitors be in this field? And any idea what their market penetration might be, for the competitors or for Kneat?
It would be for a spec buy and to initiate a 1/3 position.
Cheers,
Steve
Q: Does PTQ have good financials and growth projects .
Regards
Ed
Regards
Ed
Q: Thank you for the information on CloudMD, I accidently had it flagged as private, my follow-up question is, I was interested in the company due to the remote health services and digitizing the medical sector, I did well with a company in the past in this space but it was bought out and looking for another. I know Telus is in this space but very small compared to it's other business. Any suggestions?
Q: The company financials are straight up and profit margins seem reasonable. Can I have your opinion for a 3 to 5 year hold
GUY
GUY
Q: Hello. Looking to allocate some more capital to health care. What are your top 3 growth stock recommendations in US health care. Already own ILMN, BIIB, and MDT. Need some small to mid cap names that have good 5-10 year runways!
Q: I would like to obtain your assessment of Reliq Health Technologies with it latest report on May 29th.
Thanks 5i
Thanks 5i
Q: Cloud MD vs Well Health: is there a choice here or should I buy both?
I sold Well at $3.43 before it collapsed. New price is tempting to get back in. Thanks.
I sold Well at $3.43 before it collapsed. New price is tempting to get back in. Thanks.
Q: DOC Can you give me a summary of your views of this company
Can you also provide some technical analysis for this company? For example: The amount of Debt its carrying, etc.
Can you also provide some technical analysis for this company? For example: The amount of Debt its carrying, etc.
Q: What is your opinion of this ETF for exposure to US pharma companies? Do you have other suggestions that would be comparable/better traded in CAD.
Q: Can you please comment on IPA.V?
It has been on the rise since entering the covid-19 vaccine/therapy race. They appear to be a legitimate company not just ones of these pump and dumps targeting the latest trend.
Their last report indicated they were nearing profitability.
Thanks for your insight.
It has been on the rise since entering the covid-19 vaccine/therapy race. They appear to be a legitimate company not just ones of these pump and dumps targeting the latest trend.
Their last report indicated they were nearing profitability.
Thanks for your insight.
Q: Hi 5i
What will Sanofi’s sale of its’ stake in Regeneron do to the price of regeneron? What is the $$ value and % of the REGN market cap? (about $12b?) Will Sanofi keep any of its regeneron interests). 5i pls look at the technicals and suggest an entry point? As the sale is to be completed by December (or the lock up) should one wait?
Many thanks,
What will Sanofi’s sale of its’ stake in Regeneron do to the price of regeneron? What is the $$ value and % of the REGN market cap? (about $12b?) Will Sanofi keep any of its regeneron interests). 5i pls look at the technicals and suggest an entry point? As the sale is to be completed by December (or the lock up) should one wait?
Many thanks,
Q: I purchased AMGN - 18 months ago for $243.00. Since that time, it has come up to that level a year ago and recently twice this year. I have had the stock 18 months and I am still under water. 5i likes this stock in the health field - how much longer do you think it will take before I see a profit? On another note today the 26th - the market had the biggest run in ages, but participants (mostly tech) NVDA, PYPL, SHOP, KXS along with other techs, did not participate and went the other way. Were people selling these stocks to raise money to buy the other ones that went up? I know you will have the right answer. Thanks Dennis
Q: I have pretty much thought of GUD as a long, long term hold, and one that would be good to have in a market crisis when they could put their cash to work efficiently. But there it was and they didn't. Its starting to feel like aside from being generally close to book value, there is not much to see here. Have you had reason to rethink your position on GUD? Thank-you.
Q: These two companies are slipping instead of going up if the
they have meaningful role in Covid.
AS well Jand J maybe having issue with product liability,
Appreciate your comments on the outlook going forward
they have meaningful role in Covid.
AS well Jand J maybe having issue with product liability,
Appreciate your comments on the outlook going forward